Merck entered a $510 million collaboration with Protillion Therapeutics to leverage AI for drug discovery. Following this, the company announced that its Phase 3 ATLAS-UC study of tulisokibart successfully met its primary and key secondary endpoints. The anti-TL1A antibody demonstrated positive results in late-stage trials for patients suffering from ulcerative colitis.
